The effects of the angiotensin II receptor antagonist losartan on appetitive versus aversive learning: A randomized controlled trial

<p><strong>Background</strong><br/> Exposure therapy is a first-line treatment for anxiety disorders but remains ineffective in a large proportion of patients. A proposed mechanism of exposure involves inhibitory learning whereby the association between a stimulus and an aver...

Full description

Bibliographic Details
Main Authors: Pulcu, E, Shkreli, L, Guzman-Holst, C, Woud, ML, Craske, MG, Browning, M, Reinecke, A
Format: Journal article
Language:English
Published: Elsevier 2019
_version_ 1797080678767001600
author Pulcu, E
Shkreli, L
Guzman-Holst, C
Woud, ML
Craske, MG
Browning, M
Reinecke, A
author_facet Pulcu, E
Shkreli, L
Guzman-Holst, C
Woud, ML
Craske, MG
Browning, M
Reinecke, A
author_sort Pulcu, E
collection OXFORD
description <p><strong>Background</strong><br/> Exposure therapy is a first-line treatment for anxiety disorders but remains ineffective in a large proportion of patients. A proposed mechanism of exposure involves inhibitory learning whereby the association between a stimulus and an aversive outcome is suppressed by a new association with an appetitive or neutral outcome. The blood pressure medication losartan augments fear extinction in rodents and may have similar synergistic effects on human exposure therapy, but the exact cognitive mechanisms underlying these effects remain unknown.</p><br/> <p><strong>Methods</strong><br/> We used a reinforcement learning paradigm with compound rewards and punishments to test the prediction that losartan augments learning from appetitive relative to aversive outcomes. In a double-blind parallel design, healthy volunteers were randomly assigned to single-dose losartan (50 mg) (n = 28) versus placebo (n = 25). Participants then performed a reinforcement learning task, which simultaneously probes appetitive and aversive learning. Participant choice behavior was analyzed using both a standard reinforcement learning model and analysis of choice switching behavior.</p><br/> <p><strong>Results</strong><br/> Losartan significantly reduced learning rates from aversive events (losses) when participants were first exposed to the novel task environment, while preserving learning from positive outcomes. The same effect was seen in choice switching behavior.</p><br/> <p><strong>Conclusions</strong><br/> This study shows that losartan enhances learning from positive relative to negative events. This effect may represent a computationally defined neurocognitive mechanism by which the drug could enhance the effect of exposure in clinical populations.</p><br/>
first_indexed 2024-03-07T01:03:33Z
format Journal article
id oxford-uuid:8a8abd41-31fe-48ae-8959-766a57bb3755
institution University of Oxford
language English
last_indexed 2024-03-07T01:03:33Z
publishDate 2019
publisher Elsevier
record_format dspace
spelling oxford-uuid:8a8abd41-31fe-48ae-8959-766a57bb37552022-03-26T22:32:17ZThe effects of the angiotensin II receptor antagonist losartan on appetitive versus aversive learning: A randomized controlled trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8a8abd41-31fe-48ae-8959-766a57bb3755EnglishSymplectic Elements at OxfordElsevier2019Pulcu, EShkreli, LGuzman-Holst, CWoud, MLCraske, MGBrowning, MReinecke, A<p><strong>Background</strong><br/> Exposure therapy is a first-line treatment for anxiety disorders but remains ineffective in a large proportion of patients. A proposed mechanism of exposure involves inhibitory learning whereby the association between a stimulus and an aversive outcome is suppressed by a new association with an appetitive or neutral outcome. The blood pressure medication losartan augments fear extinction in rodents and may have similar synergistic effects on human exposure therapy, but the exact cognitive mechanisms underlying these effects remain unknown.</p><br/> <p><strong>Methods</strong><br/> We used a reinforcement learning paradigm with compound rewards and punishments to test the prediction that losartan augments learning from appetitive relative to aversive outcomes. In a double-blind parallel design, healthy volunteers were randomly assigned to single-dose losartan (50 mg) (n = 28) versus placebo (n = 25). Participants then performed a reinforcement learning task, which simultaneously probes appetitive and aversive learning. Participant choice behavior was analyzed using both a standard reinforcement learning model and analysis of choice switching behavior.</p><br/> <p><strong>Results</strong><br/> Losartan significantly reduced learning rates from aversive events (losses) when participants were first exposed to the novel task environment, while preserving learning from positive outcomes. The same effect was seen in choice switching behavior.</p><br/> <p><strong>Conclusions</strong><br/> This study shows that losartan enhances learning from positive relative to negative events. This effect may represent a computationally defined neurocognitive mechanism by which the drug could enhance the effect of exposure in clinical populations.</p><br/>
spellingShingle Pulcu, E
Shkreli, L
Guzman-Holst, C
Woud, ML
Craske, MG
Browning, M
Reinecke, A
The effects of the angiotensin II receptor antagonist losartan on appetitive versus aversive learning: A randomized controlled trial
title The effects of the angiotensin II receptor antagonist losartan on appetitive versus aversive learning: A randomized controlled trial
title_full The effects of the angiotensin II receptor antagonist losartan on appetitive versus aversive learning: A randomized controlled trial
title_fullStr The effects of the angiotensin II receptor antagonist losartan on appetitive versus aversive learning: A randomized controlled trial
title_full_unstemmed The effects of the angiotensin II receptor antagonist losartan on appetitive versus aversive learning: A randomized controlled trial
title_short The effects of the angiotensin II receptor antagonist losartan on appetitive versus aversive learning: A randomized controlled trial
title_sort effects of the angiotensin ii receptor antagonist losartan on appetitive versus aversive learning a randomized controlled trial
work_keys_str_mv AT pulcue theeffectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT shkrelil theeffectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT guzmanholstc theeffectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT woudml theeffectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT craskemg theeffectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT browningm theeffectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT reineckea theeffectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT pulcue effectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT shkrelil effectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT guzmanholstc effectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT woudml effectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT craskemg effectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT browningm effectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial
AT reineckea effectsoftheangiotensiniireceptorantagonistlosartanonappetitiveversusaversivelearningarandomizedcontrolledtrial